Pharmaron vs Tigermed

Pharmaron faces lighter direct rival pressure than Tigermed, though large parts of its business remain undisclosed, assessed July 2026.

Chinese CRO/CDMO running drug discovery, development, and manufacturing for global pharma clients

Chinese CRO running clinical trials for drugmakers, ranked among the world's largest

Dimension by dimension

Dimension	Pharmaron	Tigermed
Staying power of the core clinical trial business	No description of Pharmaron's core business is available in the data provided.	Tigermed runs clinical trials and site operations for drugmakers in China and abroad, an active service model tied to ongoing drug development spending.
Exposure to AI replacing the product	No AI exposure rating is available for Pharmaron.	Tigermed's service is marked unlikely to be absorbed by AI.
How easily a giant could copy the business	No copy risk rating is available for Pharmaron.	Tigermed is flagged as possible to copy by a larger player.
Pressure from rivals	Pharmaron has no stated source of rival pressure in the data provided, indicating comparatively lighter direct pressure than Tigermed as assessed July 2026.	Tigermed faces pressure from IQVIA's larger trial volume in China and headwinds from US-China biotech decoupling overseas.
Strength of competitive defenses	No specific competitive defense strengths are disclosed for Pharmaron in the data provided, assessed July 2026.	No specific competitive defense strengths are disclosed for Tigermed in the data provided, assessed July 2026.
Financial footing	No financial figures for Pharmaron are provided.	Tigermed posted RMB 6.83B in FY2025 revenue and RMB 10,158M in net new bookings, up 20.6% year over year, but Q1 2026 net profit fell 70.36% year over year to RMB 49.04M.

Questions people ask

Is Tigermed's clinical trial business at risk from AI?: Tigermed's service is marked unlikely to be absorbed by AI. There is no equivalent AI exposure rating available for Pharmaron in the data provided.
How do Tigermed and Pharmaron compare financially?: Tigermed reported RMB 6.83B in FY2025 revenue and RMB 10,158M in net new bookings, up 20.6% year over year, though Q1 2026 net profit dropped 70.36% year over year to RMB 49.04M. No financial figures for Pharmaron are included in the data, so a direct comparison is not possible.
Could a large competitor copy Tigermed's or Pharmaron's business?: Tigermed is flagged as possible to copy by a larger player. No such rating exists for Pharmaron in the data provided, so its copy risk is unclear.

Other comparisons with these companies